文献速递脑血管病

HIV感染成人卒中及疑似卒中的静脉溶栓:美国多中心回顾性研究

Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study.
PubMed 文献 · Stroke · 2018-01-01

该研究回顾性分析了美国7个城市学术中心2000至2017年间接受静脉tPA治疗的33例HIV感染卒中症状患者,其中10例为卒中模拟病。结果显示多数患者无并发症且无死亡,症状性出血转化仅2例(6%,95%CI 1%-20%),提示该人群溶栓可能安全。

要点

  • HIV感染者静脉tPA溶栓后非致命性出血转化率为6%(95%CI 1%-20%)。
  • 33例中10例为卒中模拟病,提示需警惕模拟病。
  • 合并机会性感染或静脉吸毒未见增加tPA相关并发症风险。

核心结论

  • 多数HIV感染卒中患者接受静脉tPA后无并发症,未观察到死亡。
  • 卒中模拟病常见,溶栓在该组中似乎安全。
  • 未发现机会性感染或静脉吸毒增加tPA相关并发症风险的数据。

研究设计与样本

  • 回顾性病历审查,纳入美国7个大型城市学术中心2000至2017年间接受静脉tPA治疗的HIV感染卒中症状患者。
  • 共识别33例HIV感染患者,平均年龄51岁,24例男性,其中10例为卒中模拟病。

主要发现

  • 就诊时NIHSS评分中位数9分,症状发作至tPA平均时间144分钟(中位数159分钟)。
  • 33例队列末次随访mRS中位数1分,23例实际卒中队列mRS中位数2分,随访中位数90天。
  • 2例发生非致命性出血转化(6%;95%CI 1%-20%),均在实际卒中组。
  • 2例中枢神经系统水痘带状疱疹病毒血管炎,1例脑膜血管梅毒,7例其他患者正在静脉吸毒(3例可卡因,1例海洛因,3例未指明),均无出血转化。

临床怎么用

  • 对于HIV感染合并急性缺血性卒中患者,静脉tPA并非绝对禁忌,但需评估卒中模拟病可能。
  • 合并机会性感染或静脉吸毒可能不增加溶栓出血风险,但仍需个体化评估。

局限性

  • 回顾性设计,样本量小(33例),来自7个中心。
  • 卒中模拟病比例较高,可能影响安全性估计。
  • 缺乏非HIV感染对照人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Human immunodeficiency virus (HIV) infection has been shown to increase both ischemic and hemorrhagic stroke risks, but there are limited data on the safety and outcomes of intravenous thrombolysis with tPA (tissue-type plasminogen activator) for acute ischemic stroke in HIV-infected patients. METHODS: A retrospective chart review of intravenous tPA-treated HIV patients who presented with acute stroke symptoms was performed in 7 large inner-city US academic centers (various search years between 2000 and 2017). We collected data on HIV, National Institutes of Health Stroke Scale score, ischemic stroke risk factors, opportunistic infections, intravenous drug abuse, neuroimaging findings, and modified Rankin Scale score at last follow-up. RESULTS: We identified 33 HIV-infected patients treated with intravenous tPA (mean age, 51 years; 24 men), 10 of whom were stroke mimics. Sixteen of 33 (48%) patients had an HIV viral load less than the limit of detection while 10 of 33 (30%) had a CD4 count <200/mm3. The median National Institutes of Health Stroke Scale score at presentation was 9, and mean time from symptom onset to tPA was 144 minutes (median, 159). The median modified Rankin Scale score for the 33-patient cohort was 1 and for the 23-patient actual stroke cohort was 2, measured at a median of 90 days poststroke symptom onset. Two patients had nonfatal hemorrhagic transformation (6%; 95% confidence interval, 1%-20%), both in the actual stroke group. Two patients had varicella zoster virus vasculitis of the central nervous system, 1 had meningovascular syphilis, and 7 other patients were actively using intravenous drugs (3 cocaine, 1 heroin, and 3 unspecified), none of whom had hemorrhagic transformation. CONCLUSIONS: Most HIV-infected patients treated with intravenous tPA for presumed and actual acute ischemic stroke had no complications, and we observed no fatalities. Stroke mimics were common, and thrombolysis seems safe in this group. We found no data to suggest an increased risk of intravenous tPA-related complications because of concomitant opportunistic infections or intravenous drug abuse.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. AbdelRazek MA, Gutierrez J, Mampre D, et al. Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study. Stroke. 2018. PMID: 29273597. doi:10.1161/STROKEAHA.117.019570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。